SEE ALSO...
Items 11 to 16 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 41-2272 | 256376-24-6 | sc-202491 sc-202491A | 5 mg 25 mg | $238.00 $728.00 | 4 | |
BAY 41-2272 sensitizes soluble guanylate cyclase to endogenous NO, resulting in elevated cGMP levels and activation of cGKIα. | ||||||
Riociguat | 625115-55-1 | sc-476845 | 5 mg | $300.00 | ||
Riociguat stimulates soluble guanylate cyclase both independently of NO and as a sensitizer to NO, causing an increase in cGMP synthesis and activation of cGKIα. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine may induce nitric oxide release, which can increase cGMP levels and subsequently enhance the activation of PKG1. | ||||||
SR 48692 | 146362-70-1 | sc-363290 sc-363290A sc-363290B sc-363290C sc-363290D | 5 mg 25 mg 100 mg 500 mg 1 g | $159.00 $605.00 $2374.00 $10710.00 $21410.00 | 2 | |
This analog increases cGMP production by activating particulate guanylyl cyclase, leading to enhanced PKG1 activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5 and possibly other cGMP-degrading phosphodiesterases, increasing cGMP levels and enhancing PKG1 activity. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, which can lead to an increase in cGMP due to reduced cGMP degradation, indirectly enhancing PKG1 activation. | ||||||